Biotech Values

[DewDiligence]

Agree with your post. On nearly every IDIX webcast, someone asks the same dumb question about whether IDIX would consider partnering all of its drug candidates in a package deal. Is it too much to expect that analysts and institutional investors perform a modicum of DD? That’s all it takes to know that NVS has the right of first negotiation on each individual compound in IDIX’s pipeline.